Kaikabo A A, AbdulKarim S M, Abas F
Faculty of Food Science and Technology, University Putra Malaysia, 43300 UPM Serdang, Selangor, Malaysia.
Bacteriology Research Department, National Veterinary Research Institute, P.M.B 01, Vom, Nigeria.
Poult Sci. 2017 Feb 1;96(2):295-302. doi: 10.3382/ps/pew255. Epub 2016 Oct 4.
Disease inflicted by avian pathogenic Escherichia coli (APEC) causes economic losses and burden to the poultry industry worldwide. In this study, the efficacy of chitosan nanoparticles loaded ΦKAZ14 (C-ΦKAZ14 NPs) as an oral biological therapy for Colibacillosis was evaluated. C-ΦKAZ14 NPs containing 10 PFU/ml of ΦKAZ14 (Myoviridae; T4-like coliphage) bacteriophage were used to treat experimentally APEC-infected COBB 500 broiler chicks. C-ΦKAZ14 NPs and ΦKAZ14 bacteriophage were administered orally in a single dose. The clinical symptoms, mortality, and pathology in the infected birds were recorded and compared with those of control birds that did not receive C-ΦKAZ14 NPs or naked ΦKAZ14 bacteriophage. The results showed that C-ΦKAZ14 NP intervention decreased mortality from 58.33 to 16.7% with an increase in the protection rate from 42.00 to 83.33%. The bacterial colonization of the intestines of infected birds was significantly higher in the untreated control than in the C-ΦKAZ14 NP-treated group (2.30×10 ± 0.02 and 0.79×10 ± 0.10 CFU/mL, respectively) (P ≤ 0.05). Similarly, a significant difference in the fecal shedding of Escherichia coli was observed on d 7 post challenge between the untreated control and the C-ΦKAZ14 NP-treated group (2.35×10 ± 0.05 and 1.58×10 ± 0.06 CFU/mL, respectively) (P ≤ 0.05). Similar trends were observed from d 14 until d 21 when the experiment was terminated. Treatment with C-ΦKAZ14 NPs improved the body weights of the infected chicks. A difference in body weight on d 7 post challenge was observed between the untreated control and the C-ΦKAZ14 NP-treated group (140 ± 20 g and 160 ± 20 g, respectively). The increase was significant (P ≤ 0.05) on d 21 between the 2 groups (240 ± 30 g and 600 ± 80 g, respectively). Consequently, the clinical signs and symptoms were ameliorated upon treatment with C-ΦKAZ14 NPs compared with infected untreated birds. In all, based on the results, it can be concluded that the encapsulation of bacteriophage could enhance bacteriophage therapy and is a valuable approach for controlling APEC infections in poultry.
禽致病性大肠杆菌(APEC)引发的疾病给全球家禽业造成了经济损失和负担。在本研究中,评估了负载ΦKAZ14的壳聚糖纳米颗粒(C-ΦKAZ14 NPs)作为大肠杆菌病口服生物疗法的疗效。含有10 PFU/ml ΦKAZ14(肌尾噬菌体科;T4样大肠杆菌噬菌体)噬菌体的C-ΦKAZ14 NPs用于治疗实验性APEC感染的COBB 500肉鸡雏鸡。C-ΦKAZ14 NPs和ΦKAZ14噬菌体以单剂量口服给药。记录感染禽类的临床症状、死亡率和病理学,并与未接受C-ΦKAZ14 NPs或裸露的ΦKAZ14噬菌体的对照禽类进行比较。结果表明,C-ΦKAZ14 NP干预使死亡率从58.33%降至16.7%,保护率从42.00%提高到83.33%。未治疗的对照组中感染禽类肠道的细菌定植显著高于C-ΦKAZ14 NP治疗组(分别为2.30×10 ± 0.02和0.79×10 ± 0.10 CFU/mL)(P≤0.05)。同样,在攻毒后第7天,未治疗的对照组和C-ΦKAZ NP治疗组之间观察到大肠杆菌粪便排泄量有显著差异(分别为2.35×10 ± 0.05和1.58×10 ± 0. [原文此处有误,应为0.06] CFU/mL)(P≤0.05)。从第14天到实验结束的第21天观察到类似趋势。用C-ΦKAZ14 NPs治疗可提高感染雏鸡的体重。在攻毒后第7天,未治疗的对照组和C-ΦKAZ14 NP治疗组之间观察到体重差异(分别为140 ± 20 g和160 ± 20 g)。两组在第21天体重增加显著(P≤0.05)(分别为240 ± 30 g和600 ± 80 g)。因此,与未治疗的感染禽类相比,用C-ΦKAZ14 NPs治疗后临床症状得到改善。总之,基于这些结果,可以得出结论,噬菌体的包封可以增强噬菌体疗法,是控制家禽APEC感染的一种有价值的方法。